Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR: Rilvegostomig Combinations in Advanced or Metastatic NSCLC
NCT06996782Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Primary completion
- Feb 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 2, randomised, open-label trial of rilvegostomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events and Serious Adverse Events at 46 months, Dose Limiting Toxicity at 46 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06996782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996782.